UBS AM’s Definium Therapeutics DFTX Stock Holding History

UBS AM’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$45.6K	Buy	2,413 +1,519	+170%	+$25.8K	﹤0.01%	2975
2025 Q4	$12K	Sell	894 -116,345	-99%	-$1.44M	﹤0.01%	2820
2025 Q3	$1.38M	Buy	117,239 +75,110	+178%	+$700K	﹤0.01%	1890
2025 Q2	$273K	Sell	42,129 -3,492	-8%	-$23K	﹤0.01%	2532
2025 Q1	$267K	Sell	45,621 -39,423	-46%	-$282K	﹤0.01%	2561
2024 Q4	$592K	Buy	85,044 +14,691	+21%	+$101K	﹤0.01%	2527
2024 Q3	$400K	Sell	70,353 -7,726	-10%	-$53.7K	﹤0.01%	2682
2024 Q2	$563K	Buy	+78,079	New	+$683K	﹤0.01%	2598
2021 Q3	–	Sell	-10,867	Closed	-$567K	–	2764
2021 Q2	$567K	Buy	+10,867	New	+$570K	﹤0.01%	2488

Other funds holding DFTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS AM's DFTX Position: Q1 2026 in Review

UBS AM increased its Definium Therapeutics (DFTX) stake by 170% in Q1 2026, buying an estimated $25.8K and bringing the position to 2,413 shares worth $45.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2975.

UBS AM first reported a position in DFTX in Q2 2021 and has held it in 9 quarters since. The position peaked at $1.38M in Q3 2025. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

UBS AM held 2,413 shares of Definium Therapeutics worth $45.6K as of Q1 2026.
UBS AM bought 1,519 Definium Therapeutics shares in Q1 2026, an estimated $25.8K.
Definium Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q1 2026, its #2975 holding.
UBS AM first reported a position in Definium Therapeutics in Q2 2021 and has held it in 9 quarters since.
UBS AM's Definium Therapeutics position peaked at $1.38M in Q3 2025.
247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on UBS AM's 13F filing for Q1 2026, filed 13 May 2026.